Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 158 participants.

Also called NCT01625494

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 158 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01625494
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01625494. Randomized; no masking; primary purpose treatment. Start 2012-05 (registry gives no type); primary completion 2013-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy
Condition
Hypertension
Intervention (Drug)
Irbesartan/Amlodipine (150/5mg)
Intervention (Drug)
Irbesartan/Amlodipine (150/10mg)
Intervention (Drug)
Irbesartan/Amlodipine (300/5mg)
Intervention (Drug)
Irbesartan/Amlodipine (300/10mg)
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01625494
Content hash
28f49200cb88c0a1609016ecfaf132648d31a923b894cc8da0b6cd2fcdbb35ec